血漿由来医薬品の世界市場

血漿由来医薬品の世界市場は2030年までに251億米ドルに達する見込み

2024年に179億米ドルと推定される血漿由来医薬品の世界市場は、2024～2030年の分析期間においてCAGR 5.7%で成長し、2030年には251億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである免疫グロブリンは、CAGR4.6%を記録し、分析期間終了時には97億米ドルに達すると予想されます。凝固因子セグメントの成長率は、分析期間中CAGR 7.1%と推定されます。

米国市場は49億米ドルと推定、中国はCAGR 8.8％で成長予測

米国の血漿由来医薬品市場は、2024年に49億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.8%で推移し、2030年までに50億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と5.6%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

世界の血漿由来医薬品市場- 主要動向と促進要因のまとめ

血漿由来医薬品が希少疾患や慢性疾患の治療に欠かせない理由とは？

提供されたヒト血漿を分画することで得られる血漿由来医薬品は、血友病、原発性免疫不全症、遺伝性血管性浮腫、自己免疫疾患など、生命を脅かす様々な慢性疾患の治療に重要な役割を果たしています。これらの生物製剤には、免疫グロブリン（IVIG/SCIG）、凝固因子（血液凝固第VIII因子、血液凝固第IX因子）、アルブミン、暴露後予防に使用される高免疫グロブリンなどが含まれます。合成医薬品とは異なり、血漿由来療法は低分子代替品では代替できない複雑な生物製剤であり、多くの場合、患者にとって唯一の治療選択肢であり続けています。

免疫不全症や稀な出血性疾患の世界の蔓延に伴い、その重要性は増しています。特に、診断能力が拡大し、新生児スクリーニングプログラムによって罹患者が早期に特定されるようになったことが大きいです。さらに、血漿をベースとした治療法は、敗血症性ショック、ギランバレー症候群、移植後の免疫調節など、適応外治療やクリティカルケアの場面でますます使用されるようになっています。慢性的な免疫疾患を抱えながら長生きする人口が世界的に増加する中、血漿蛋白質への医療依存度は高まり続けており、需要とサプライチェーンの双方に上昇圧力がかかっています。

サプライチェーンを形成する技術的・経営的課題とは？

血漿由来医薬品の製造は、厳格なドナースクリーニング、血漿採取、病原体不活化、コールドチェーン物流を含む、高度に専門的で資源集約的なプロセスです。血漿タンパク質を分離する工程である分画は、複数の精製・検証工程があるため、採取から最終製品まで7～12ヶ月かかります。この長いリードタイムが、厳格な生物学的標準やバッチのばらつきと相まって、この業界を非常に資本集約的でコンプライアンス重視の業界にしています。血漿の提供が世界的に大幅に減少したCOVID-19パンデミックの際に見られたように、ドナーの入手や施設の運営に支障が生じると、下流の供給ボトルネックにつながる可能性があります。

クロマトグラフィー、ウイルス濾過、ナノ濾過における技術の進歩は、血漿誘導体の収率、純度、安全性を向上させています。自動化されたプラズマフェレーシスシステムとデジタルドナー関与ツールは、収集効率を高めています。しかしながら、これらの進歩の拡張性は、血漿の生物学的性質によって制約を受ける。さらに、病原体の安全性は依然として最優先事項であり、規制上の義務として、溶媒-洗剤処理や加熱低温殺菌など、複数のウイルス不活化工程が必要となり、すべての製品にコストと複雑さが加わる。このような現実が世界の血漿供給の不均衡を招き、新興国市場は特に米国の少数の大規模ドナーネットワークに大きく依存しています。

世界の需要の高まりに市場リーダーや政府はどう対応しているか？

増大する需要に対応するため、バイオ医薬品企業は血漿採取センターの拡張、分画能力のアップグレード、製造の地域化に多額の投資を行い、より良いアクセスと供給の回復力を確保しています。CSLベーリング、グリフォルス、武田薬品、オクタファーマなどの業界大手は、独立した収集ネットワークを買収し、血漿バンクを構築し、ドナー支援活動をデジタルヘルスプラットフォームと統合しています。これらの会社はまた、東南アジア、ラテンアメリカ、東欧など、血漿へのアクセスが十分でない地域で血漿へのアクセスを改善するために、官民パートナーシップを形成しています。

政府や規制機関は、国内の血漿供給の安全性を守るための措置を講じています。欧州委員会の血液・血漿イニシアチブ（Blood and Plasma Initiative）や米国HHSが支援する血漿蛋白質治療協会（PPTA）などのイニシアチブは、自発的な献血を奨励し、償還モデルを改善し、地域の収集インフラにインセンティブを与えています。世界保健機関（WHO）は、特に中低所得国において、自給自足戦略の開発を呼びかけており、輸入品への依存は、患者を欠乏や価格ショックの影響を受けやすくします。一方、新興のバイオテクノロジー企業は、ヒト血漿への依存を減らすため、組み換え代替品や合成生物学的アプローチを模索しているが、そうした製品はまだ初期の臨床段階にあります。

血漿由来医薬品市場の長期的成長の原動力は？

世界の血漿由来医薬品市場の成長は、免疫不全や希少血液疾患の有病率の上昇、世界の診断能力の向上、適応外適用の拡大など、いくつかの要因によってもたらされます。神経学や自己免疫治療におけるIVIGの使用増加、肝疾患やクリティカルケアにおけるアルブミンの需要拡大により、市場は従来の血液学の基盤を大きく超えて拡大しています。また、特に先進諸国では人口の高齢化が進んでおり、高齢患者は加齢に伴う免疫低下に対して免疫グロブリン療法を必要とするため、治療量の増加にも寄与しています。

さらに、血漿の安全性に対する規制当局の強力な支援、献血に対する一般市民の意識の高まり、大手バイオ製薬会社による戦略的投資により、サプライチェーンが強化されています。受託血漿分画サービス、デジタルドナー関与ツール、個別化治療レジメンの成長は、より良い生産計画と治療のカスタマイズを可能にしています。さらに、新興国の血漿収集・製造分野への参入により、世界のアクセシビリティの向上と地域格差の縮小が期待されます。慢性疾患の管理が生物製剤中心になり、世界の医療制度が希少疾患におけるケアの継続を優先するようになるにつれて、血漿由来医薬品は今後数年間、力強く持続的な成長を遂げる態勢が整っています。

セグメント

製品（免疫グロブリン、凝固因子、アルブミン、その他製品）、流通チャネル（病院薬局、小売薬局、オンライン薬局）、用途（骨盤内炎症性疾患、出血性疾患、α1アンチトリプシン欠損症、遺伝性血管性浮腫、慢性炎症性脱髄性多発神経炎、ギランバレー症候群、多巣性運動ニューロパチー、肝疾患、原発性免疫性血小板減少症、その他用途）

調査対象企業の例（全34件）

• ADMA Biologics, Inc.
• Aurobindo Pharma Limited
• Baxter International Inc.
• Bharat Serums and Vaccines Limited
• Bio Products Laboratory Ltd（BPL）
• Biotest AG
• CSL Behring
• China Biologic Products Holdings, Inc.
• Fusion Healthcare
• Grifols, S.A.
• Hualan Biological Engineering Inc.
• Kamada Ltd.
• Kedrion Biopharma
• LFB S.A.
• Octapharma AG
• Panacea Biotec
• Sanquin
• Shanghai RAAS Blood Products Co., Ltd.
• SK Plasma
• Takeda Pharmaceutical Company Limited

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Plasma-Derived Medicines Market to Reach US$25.1 Billion by 2030

The global market for Plasma-Derived Medicines estimated at US$17.9 Billion in the year 2024, is expected to reach US$25.1 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Immunoglobulin, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the Coagulation Factors segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 8.8% CAGR

The Plasma-Derived Medicines market in the U.S. is estimated at US$4.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.0 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Plasma-Derived Medicines Market - Key Trends & Drivers Summarized

Why Are Plasma-Derived Medicines Critical in Treating Rare and Chronic Disorders?

Plasma-derived medicines, obtained through fractionation of donated human plasma, play a vital role in managing a range of life-threatening and chronic conditions, including hemophilia, primary immunodeficiencies, hereditary angioedema, and autoimmune disorders. These biologics include immunoglobulins (IVIG/SCIG), clotting factors (Factor VIII, Factor IX), albumin, and hyperimmune globulins used in post-exposure prophylaxis. Unlike synthetic drugs, plasma-derived therapies are complex biologics that cannot be replaced with small-molecule alternatives, and in many cases, they remain the only therapeutic option available for patients.

Their importance has grown with the increasing global prevalence of immunodeficiencies and rare bleeding disorders, particularly as diagnostic capabilities expand and newborn screening programs identify affected individuals earlier. Additionally, plasma-based therapies are being increasingly used in off-label and critical care settings, such as septic shock, Guillain-Barre syndrome, and post-transplant immunomodulation. With a growing global population living longer with chronic immune conditions, the medical reliance on plasma proteins continues to intensify, creating upward pressure on both demand and supply chains.

What Are the Technological and Operational Challenges Shaping the Supply Landscape?

The production of plasma-derived medicines is a highly specialized, resource-intensive process involving rigorous donor screening, plasma collection, pathogen inactivation, and cold-chain logistics. Fractionation, the process of separating plasma proteins, takes 7-12 months from collection to final product due to multiple purification and validation steps. This extended lead time, combined with strict biological standards and batch variability, makes the industry highly capital- and compliance-intensive. Any disruption in donor availability or facility operations can result in downstream supply bottlenecks, as witnessed during the COVID-19 pandemic when plasma donations declined significantly worldwide.

Technological advances in chromatography, virus filtration, and nanofiltration are improving the yield, purity, and safety of plasma derivatives. Automated plasmapheresis systems and digital donor engagement tools are enhancing collection efficiency. However, the scalability of these advancements is constrained by the biological nature of plasma-each batch is unique, and consistent manufacturing outcomes require continuous quality control. Moreover, pathogen safety remains a top priority; regulatory mandates necessitate multiple virus inactivation steps, including solvent-detergent treatment and heat pasteurization, which add cost and complexity to every product. These operational realities have led to a global plasma supply imbalance, with developed markets heavily reliant on a few large-scale donor networks, especially in the U.S.

How Are Market Leaders and Governments Responding to Rising Global Demand?

To address growing demand, biopharmaceutical companies are investing heavily in expanding plasma collection centers, upgrading fractionation capacities, and regionalizing manufacturing to ensure better access and supply resilience. Industry leaders such as CSL Behring, Grifols, Takeda, and Octapharma are acquiring independent collection networks, building plasma banks, and integrating donor outreach with digital health platforms. These companies are also forming public-private partnerships to improve plasma access in underrepresented geographies, such as Southeast Asia, Latin America, and Eastern Europe.

Governments and regulatory bodies are taking steps to safeguard national plasma supply security. Initiatives such as the European Commission’s Blood and Plasma Initiative and the U.S. HHS-supported Plasma Protein Therapeutics Association (PPTA) are encouraging voluntary donation, improving reimbursement models, and incentivizing local collection infrastructure. The World Health Organization has called for the development of national self-sufficiency strategies, particularly in low- and middle-income countries, where reliance on imported products leaves patients vulnerable to shortages and price shocks. Meanwhile, emerging biotech firms are exploring recombinant alternatives and synthetic biology approaches to reduce dependency on human plasma, although such products are still in early clinical phases.

What’s Powering the Long-Term Growth of the Plasma-Derived Medicines Market?

The growth in the global plasma-derived medicines market is driven by several factors, including rising prevalence of immunodeficiencies and rare hematological disorders, improved global diagnostic capabilities, and expanding off-label applications. The increasing use of IVIG in neurology and autoimmune therapies, alongside growing demand for albumin in liver disease and critical care, is significantly expanding the market beyond its traditional hematology base. Aging populations, particularly in developed countries, are also contributing to higher treatment volumes, as older patients require immunoglobulin therapies for age-associated immune decline.

Furthermore, strong regulatory support for plasma safety, increasing public awareness of donation, and strategic investments by major biopharma companies are reinforcing supply chains. Growth in contract plasma fractionation services, digital donor engagement tools, and personalized therapy regimens is enabling better production planning and treatment customization. Additionally, the entry of emerging economies into the plasma collection and manufacturing space is expected to improve global accessibility and reduce regional disparities. As chronic disease management becomes more biologics-centric, and as global health systems prioritize continuity of care in rare disorders, plasma-derived medicines are poised for robust, sustained growth in the years ahead.

SCOPE OF STUDY:

The report analyzes the Plasma-Derived Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Immunoglobulin, Coagulation Factors, Albumin, Other Products); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Application (Pelvic Inflammatory Disease, Bleeding Disorders, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• ADMA Biologics, Inc.
• Aurobindo Pharma Limited
• Baxter International Inc.
• Bharat Serums and Vaccines Limited
• Bio Products Laboratory Ltd (BPL)
• Biotest AG
• CSL Behring
• China Biologic Products Holdings, Inc.
• Fusion Healthcare
• Grifols, S.A.
• Hualan Biological Engineering Inc.
• Kamada Ltd.
• Kedrion Biopharma
• LFB S.A.
• Octapharma AG
• Panacea Biotec
• Sanquin
• Shanghai RAAS Blood Products Co., Ltd.
• SK Plasma
• Takeda Pharmaceutical Company Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Plasma-Derived Medicines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Immunoglobulins and Coagulation Factors Drives Growth in Plasma-Derived Medicines
  • Expansion of Rare Disease Diagnosis and Management Throws the Spotlight on Plasma Therapies
  • Innovation in Fractionation and Purification Processes Enhances Yield and Product Safety
  • Growth in Hemophilia, Primary Immunodeficiency, and Autoimmune Indications Spurs Clinical Demand
  • Collaboration With Blood Banks and Plasma Collection Networks Strengthens Supply Chain Security
  • Increasing Use of Albumin in Surgical and Trauma Care Expands Application Base in Critical Care
  • Investment in Pathogen Inactivation and Virus Filtration Enhances Regulatory Compliance
  • Surge in Demand for Intravenous and Subcutaneous Immunoglobulin Drives Manufacturing Capacity Expansion
  • Focus on Global Collection Infrastructure and Donor Pool Diversification Improves Supply Resilience
  • Rising Pressure to Meet cGMP and Pharmacopoeia Standards Spurs Facility Modernization Across Regions
  • Participation in Public-Private Partnerships Enhances Access to Plasma-Derived Therapies in LMICs
  • Growth in Transplantation and Neurological Indications Expands Indirect Demand for Plasma Derivatives
  • Entry Into Recombinant-Paired Product Pipelines Enhances Multi-Modality Therapy Options
  • Increasing Interest in Hyperimmune Globulins and Pandemic Readiness Strategies Strengthens Niche Markets
  • Emphasis on Donor Recruitment, Retention, and Plasma Incentivization Supports Collection Scale-Up
  • Rising Regulatory Harmonization Among FDA, EMA, and WHO Accelerates Product Approvals and Global Reach
  • Development of Long-Acting and Ready-to-Use Formats Enhances Patient Convenience and Compliance
  • Growth in Patient Advocacy and Reimbursement Campaigns Strengthens Policy Support for Plasma Therapies
  • Differentiation Through Orphan Drug Designation and Expanded Indication Approvals Boosts Market Position
  • Global Shift Toward Self-Administration and Home Infusion Solutions Propels Device-Integrated Plasma Drug Delivery
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Plasma-Derived Medicines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Plasma-Derived Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Coagulation Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Coagulation Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Coagulation Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Alpha-1 Antitrypsin Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Alpha-1 Antitrypsin Deficiency by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Alpha-1 Antitrypsin Deficiency by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Chronic Inflammatory Demyelinating Polyneuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Chronic Inflammatory Demyelinating Polyneuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Chronic Inflammatory Demyelinating Polyneuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Guillain-Barre Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Guillain-Barre Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Guillain-Barre Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Multifocal Motor Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Multifocal Motor Neuropathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Multifocal Motor Neuropathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Primary Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Primary Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Primary Immune Thrombocytopenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Pelvic Inflammatory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Pelvic Inflammatory Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Pelvic Inflammatory Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Bleeding Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Bleeding Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Bleeding Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Plasma-Derived Medicines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 131: UK Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 137: UK Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 146: Spain Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Spain Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Spain 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 155: Russia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Russia Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Russia 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Rest of Europe Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Rest of Europe 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Plasma-Derived Medicines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Asia-Pacific Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Australia 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 185: Australia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Australia Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Australia 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 188: India Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 191: India Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: India 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 194: India Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: India Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: India 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: South Korea 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 203: South Korea Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: South Korea Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: South Korea 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Asia-Pacific Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Plasma-Derived Medicines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Latin America 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 224: Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Latin America Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Latin America 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Argentina 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 233: Argentina Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Argentina Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Argentina 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Brazil 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 242: Brazil Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Brazil Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Brazil 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Mexico 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 251: Mexico Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Mexico Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Mexico 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Latin America Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Latin America 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Plasma-Derived Medicines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Plasma-Derived Medicines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Middle East 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 272: Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Middle East Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Middle East 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Iran 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 281: Iran Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Iran Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Iran 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Israel 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 290: Israel Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Israel Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Israel 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Saudi Arabia Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Saudi Arabia 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: UAE 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 308: UAE Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: UAE Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: UAE 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Middle East Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Middle East 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Plasma-Derived Medicines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Plasma-Derived Medicines by Product - Immunoglobulin, Coagulation Factors, Albumin and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Plasma-Derived Medicines by Product - Percentage Breakdown of Value Sales for Immunoglobulin, Coagulation Factors, Albumin and Other Products for the Years 2015, 2025 & 2030
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Plasma-Derived Medicines by Application - Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Africa 15-Year Perspective for Plasma-Derived Medicines by Application - Percentage Breakdown of Value Sales for Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Other Applications, Pelvic Inflammatory Disease and Bleeding Disorders for the Years 2015, 2025 & 2030
  • TABLE 326: Africa Recent Past, Current & Future Analysis for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Africa Historic Review for Plasma-Derived Medicines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Africa 15-Year Perspective for Plasma-Derived Medicines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION